NLE Community Health Nursing — Communicable Disease Control & ImmunizationStudy Notes

Prevention is the foundation of community health nursing practice and forms the basis for all communicable disease control strategies in the Philippines. The World Health Organization (WHO) and the Philippine Department of Health (DOH) classify prevention into three levels, each with specific nursing interventions and outcomes. **Primary Prevention** occurs before disease exposure or onset and focuses on health promotion and disease prevention in the general population. Primary prevention includes health education about transmission routes and risk factors, immunization programs (the cornerstone of communicable disease control), environmental sanitation and safe water supply, adequate nutrition to support immune function, and vector control measures. For example, teaching a community about the dengue vector (Aedes aegypti) breeding in stagnant water, distributing bed nets for malaria prevention, and administering childhood vaccines are all primary prevention activities. Primary prevention is the most cost-effective and preferred level of intervention because it prevents disease from occurring in the first place, reducing the burden on the healthcare system and preventing suffering. **Secondary Prevention** begins after disease has occurred but aims to detect it early before symptoms become severe, allowing prompt treatment to limit complications and prevent transmission. Secondary prevention includes case-finding and screening programs (such as tuberculosis screening in high-risk groups), contact tracing and isolation of infectious cases, early diagnosis through laboratory testing or clinical assessment, and prompt initiation of appropriate treatment. In the context of TB control, identifying and treating a sputum-positive patient quickly prevents transmission to household members and the community. Similarly, detecting dengue cases early and referring them for fluid management prevents progression to dengue hemorrhagic fever or dengue shock syndrome. The nurse plays a critical role in community education about warning signs that prompt people to seek early care. **Tertiary Prevention** addresses the aftermath of disease and focuses on limiting disability, preventing complications, and facilitating rehabilitation and reintegration. Tertiary prevention includes managing the chronic effects of infection (such as supporting a leprosy patient with nerve damage to prevent ulceration and maintain function), rehabilitative care for polio survivors, counseling and psychosocial support for patients with stigmatized diseases like leprosy or TB, and community reintegration programs. Tertiary prevention recognizes that once disease has occurred, the goal shifts to maximizing function and quality of life. **Immunization** exemplifies the most effective form of **primary prevention—specific protection**. By introducing antigen through vaccines before natural exposure to the disease, the body develops specific antibodies and immune memory. This protects the individual (direct protection) and, when coverage is high enough to achieve herd immunity, protects even unvaccinated vulnerable individuals in the community (indirect protection).

Understanding immunity mechanisms is essential for interpreting vaccine response, counseling parents about vaccine safety, and recognizing contraindications. Immunity occurs when the body or a person develops protection against a specific pathogen. There are four main types of immunity, classified by source and speed of onset. **Active Immunity** develops when the body produces its own antibodies and cellular immune responses in response to antigen exposure. Active immunity is durable and long-lasting—sometimes lifelong—because the body has generated memory B cells and T cells that can rapidly respond to future exposure. Active immunity develops slowly over weeks to months as the immune system mounts a primary response, so there is no immediate protection. However, upon re-exposure to the same antigen (boosters or natural re-infection), a faster, stronger secondary immune response occurs. *Natural active immunity* results from surviving a natural infection with the pathogen. For example, a child who recovers from measles develops natural active immunity to measles for life. The advantage is robust immunity; the disadvantage is the risk of severe disease or death during the infection itself. *Artificial active immunity* is acquired through vaccination with a vaccine (containing antigen or weakened/inactivated pathogen) or toxoid (inactivated bacterial toxin). Vaccination induces the same protective response as natural infection without the risk of severe disease. Vaccines are the foundation of the Expanded Program on Immunization and are the primary tool for communicable disease control in the Philippines. **Passive Immunity** occurs when antibodies produced by another individual or animal are transferred directly to the recipient. Passive immunity provides immediate protection because antibodies are already present in the circulation, offering within hours to days. However, passive immunity is temporary—antibodies gradually degrade over weeks to months, and the recipient's own immune system has not been stimulated to produce memory cells. Passive immunity is useful for post-exposure prophylaxis or for short-term protection of vulnerable individuals who cannot receive active vaccines. *Natural passive immunity* is provided by maternal antibodies. During pregnancy, IgG antibodies cross the placenta and protect the fetus in utero. After birth, maternal antibodies in colostrum and breast milk (primarily IgA) provide mucosal immunity, protecting the infant's respiratory and gastrointestinal tracts. Maternal antibodies provide protection during the first 3–6 months of life for most diseases, which is why vaccination begins at 6 weeks after maternal antibodies have waned. However, maternal antibodies to measles can persist longer and may interfere with measles vaccine at 9 months, which is why a second dose (MMR) is given at 12 months after maternal immunity has fully declined. *Artificial passive immunity* is provided through administration of antibodies in the form of immunoglobulins (Ig) or antisera. For example, human immunoglobulin (tetanus immunoglobulin, rabies immunoglobulin, hepatitis B immunoglobulin) provides immediate post-exposure prophylaxis or therapeutic benefit. These are used when active immunity cannot be mounted in time or when active immunity is inadequate. Passive immunization is expensive and reserved for high-risk exposures (such as rabies exposure in an unvaccinated individual or tetanus exposure in a non-immune person). **Herd Immunity** (also called community immunity) is a critical concept in vaccination programs. When a sufficiently high proportion of a population is immune to a disease, the overall transmission of that disease is reduced. This creates a "protective barrier" around unvaccinated or vaccine-non-responders (infants too young to vaccinate, immunocompromised individuals, or rare vaccine failures) because there are fewer infected individuals to transmit the disease. The herd immunity threshold varies by disease—for measles, approximately 95% of the population must be immune; for polio, approximately 90%; for diphtheria, lower coverage may suffice. This is why achieving high immunization coverage is essential: it protects not just vaccinated individuals but also vulnerable community members who cannot be vaccinated. The Philippines aims for >95% coverage of key vaccines under the EPI to maintain herd immunity and prevent outbreaks.

The Expanded Program on Immunization (EPI) is a cornerstone of Philippine public health and is heavily tested on the NLE. The program was officially launched by the Philippine Department of Health in **1976** with the goal of reducing morbidity and mortality in children from vaccine-preventable diseases. The EPI is underpinned by two key pieces of legislation: **Presidential Decree 996** (compulsory basic immunization for children under 8 years of age) and **Republic Act 10152, the Mandatory Infants and Children Health Immunization Act of 2011**, which mandates free routine immunization for all infants and children in the Philippines and specifically mandates hepatitis B vaccination within 24 hours of birth. **Original Target Diseases (The Classic Six):** The original six vaccine-preventable diseases targeted by the EPI were tuberculosis (TB), diphtheria, pertussis (whooping cough), tetanus, poliomyelitis (polio), and measles. These six diseases caused significant morbidity, mortality, and disability in children before vaccination. Over the decades, the program has expanded to include hepatitis B, Haemophilus influenzae type b (Hib), pneumococcal disease, and other pathogens. Current coverage includes protection against 12 vaccine-preventable diseases. **Current Routine Infant Immunization Schedule (Age-Based):** The following vaccines are administered according to the current Philippine DOH schedule: **At Birth (within 24 hours):** - Bacille Calmette-Guérin (BCG): 1 dose - Hepatitis B (monovalent birth dose): 1 dose **At 6 weeks (second visit), 10 weeks (third visit), and 14 weeks (fourth visit):** - Pentavalent vaccine (DPT–HepB–Hib): 3 doses - Oral Polio Vaccine (OPV): 3 doses - Pneumococcal Conjugate Vaccine (PCV): 3 doses - Minimum interval between doses: 4 weeks **At 9 months:** - Inactivated Polio Vaccine (IPV): 1 dose - Measles-Containing Vaccine (MCV1 / AMV or MMR): 1 dose **At 12 months:** - MMR (Measles-Mumps-Rubella) / MCV2: 1 dose Additional doses and catch-up schedules apply for older children and for those with delayed initiation. **Key Vaccine Details:** **BCG (Bacille Calmette-Guérin):** - Given at birth or as early as possible after birth - Dose: 0.05 mL for infants (intradermal); 0.1 mL for children ≥1 year - Route: Intradermal injection in the right upper arm (deltoid area) - A successful take produces a wheal at the injection site; several weeks later, a small scar develops (the characteristic BCG scar). Absence of a scar does not necessarily indicate vaccine failure. - **Koch's phenomenon** or **PPD reaction** refers to an exaggerated local reaction in individuals with prior TB exposure, indicating previous or active TB infection; this is an important clinical sign that warrants TB investigation. **Hepatitis B (Birth Dose):** - Given within 24 hours of birth (or as soon as possible, up to 7 days) - Dose: 0.5 mL - Route: Intramuscular injection into the vastus lateralis (anterolateral thigh) in newborns - Protects the infant from mother-to-child transmission of hepatitis B **Pentavalent Vaccine (DPT–HepB–Hib):** - Contains diphtheria, pertussis, tetanus (DPT) + hepatitis B + Haemophilus influenzae type b antigens - Administered at 6, 10, and 14 weeks (3 doses, 4-week minimum interval) - Dose: 0.5 mL - Route: Intramuscular injection into the vastus lateralis - Replaces the older DPT vaccine and simultaneously provides hepatitis B and Hib protection - Side effects: Mild fever, local pain/swelling at injection site; severe reactions (e.g., convulsions, shock) within 3 days are rare and are a contraindication to further pentavalent doses **Oral Polio Vaccine (OPV):** - Live attenuated (weakened) oral vaccine - Administered at 6, 10, and 14 weeks (3 doses) - Dose: 2–3 drops (mouth administration) - Route: Oral (placed directly in the mouth) - **Most heat-sensitive vaccine** in the cold chain—requires the strictest temperature control - Provides both individual and herd immunity - Rare adverse event: vaccine-associated paralytic poliomyelitis (VAPP) in severely immunocompromised recipients **Inactivated Polio Vaccine (IPV):** - Inactivated (killed) vaccine - Given at 14 weeks (same visit as third pentavalent/OPV) and at 9 months - Dose: 0.5 mL - Route: Intramuscular injection into the vastus lateralis - No live virus; safe for severely immunocompromised children - Two IPV doses provide protection; additional doses may be given to complete the polio series **Pneumococcal Conjugate Vaccine (PCV13 or PCV10, depending on availability):** - Protects against invasive pneumococcal disease, pneumonia, and otitis media - Administered at 6, 10, and 14 weeks (3 doses) - Dose: 0.5 mL - Route: Intramuscular injection into the vastus lateralis - Conjugate vaccines are safe even in young infants because the polysaccharide antigens are conjugated to carrier proteins that enhance immune response **Measles-Containing Vaccine (MCV1 / AMV–Attenuated Measles Vaccine, or MMR–Measles-Mumps-Rubella):** - First dose (MCV1) given at 9 months - Live attenuated vaccine - Dose: 0.5 mL - Route: Subcutaneous injection, typically in the outer upper arm (deltoid area) - **Second dose (MMR) given at 12 months** to ensure protection after maternal antibodies decline - **Critical point:** Maternal antibodies to measles may interfere with vaccine response if given before 9 months; by 12 months, maternal immunity has typically waned, and the second dose provides a booster effect - Side effects: Low-grade fever 7–10 days post-vaccination; mild rash; lymphadenopathy. Severe allergic reactions are rare. **Tetanus (Td) Immunization for Women of Childbearing Age and Pregnant Women:** To prevent maternal tetanus and especially neonatal tetanus (tetanus in newborns born to non-immunized mothers), women are immunized with tetanus-containing vaccines: | Dose | Timing | Protection Duration | Notes | |---|---|---|---| | **Td1** | As early as possible during pregnancy | No protection yet | Initiates primary response | | **Td2** | At least 4 weeks after Td1 | ~3 years; protects newborn from neonatal tetanus | Two doses are sufficient for newborn protection | | **Td3** | At least 6 months after Td2 | ~5 years | Extended maternal protection | | **Td4** | At least 1 year after Td3 | ~10 years | Long-term protection | | **Td5** | At least 1 year after Td4 | Lifetime protection | Gold standard; not always achieved in resource-limited settings | Key point: **Td2 (a single booster dose after the first dose) already provides approximately 3 years of protection and protects the newborn from neonatal tetanus.** This is why minimum Td2 coverage targets are often set: even incomplete coverage with two doses prevents this serious, often fatal neonatal disease. Neonatal tetanus remains a major cause of neonatal mortality in low-resource regions and is a tragedy that is entirely preventable through maternal immunization. **Fully Immunized Child (FIC) and Completely Immunized Child (CIC):** A **Fully Immunized Child (FIC)** is defined as a child who, **before reaching 12 months (1 year) of age**, has received: - 1 dose of BCG - 3 doses of OPV - 3 doses of Pentavalent (DPT–HepB–Hib) - At least 1 dose of measles-containing vaccine (MCV1 at 9 months) A **Completely Immunized Child (CIC)** completes these same antigens but by **12–23 months** of age (after the first birthday, up to the second birthday). These definitions are used in DOH reports and epidemiological surveillance to track coverage and guide additional catch-up campaigns. **Child Protected at Birth (CPAB)** is a term used to describe a newborn whose mother received adequate tetanus immunization (Td2 or more) during pregnancy or prior to the last pregnancy. CPAB status is critical for neonatal tetanus prevention and is monitored in maternal health programs. **Contraindications to Immunization:** True contraindications are **rare**, and the most common reason for delayed vaccination is actually a false contraindication (missed opportunity). Nurses must distinguish between true contraindications and minor conditions that should **not** prevent vaccination: **Do NOT withhold vaccines for:** - Minor illness with or without low-grade fever (<38.5°C) - Mild diarrhea or constipation - Mild cough or upper respiratory infection - Recent exposure to a communicable disease - Jaundice in newborns - Family history of adverse vaccine reactions - Breastfeeding or recent immunization with another vaccine Vaccinating a child with minor illness is safe and prevents missed opportunities that reduce coverage. **True contraindications include:** - **Severe allergic reaction** (anaphylaxis) to a previous dose or vaccine component - **BCG should not be given to a child with clinical AIDS** (CD4 <200) or symptomatic HIV infection because it is a live vaccine and may cause disseminated BCG infection - **Live vaccines (OPV, measles/MMR, varicella, rotavirus) should not be given to severely immunocompromised children** (e.g., those on chemotherapy, with severe primary immunodeficiency, or CD4 <200 in HIV) - **Pentavalent, DPT, or other inactivated vaccines may be deferred if the previous dose caused severe adverse reaction** (severe local reaction, convulsions, or shock within 72 hours), pending further evaluation; however, inactivated vaccines are generally safe to give even to mildly ill or immunocompromised children The overarching principle is: **Vaccination may proceed despite fever or mild illness to prevent missed opportunities. True contraindications are rare.**

The cold chain is the system of equipment, procedures, and personnel responsible for maintaining vaccines within the safe temperature range from manufacturer to the point of administration. The cold chain is critical to vaccine potency and efficacy. Vaccines are heat-labile (sensitive to elevated temperatures) or freeze-sensitive (damaged by freezing), so proper storage and handling are essential. A vaccine exposed to temperatures outside the safe range may lose potency without any visible change in appearance, rendering it ineffective and leaving a vaccinated child unprotected without the knowledge of the healthcare provider or parent. **Temperature Standards by Level:** - **Health Center / Rural Health Unit (RHU):** Refrigerators should maintain **+2°C to +8°C** (cold but not freezing). This is the "cold chain point" where vaccines are stored before use. - **Regional / Provincial Storage:** Freezers should maintain **−15°C to −25°C** to preserve vaccine stock before distribution. At this level, only OPV and measles vaccines are stored in the freezer; other vaccines must be kept in the refrigerator section because they are freeze-sensitive. **Heat and Freeze Sensitivity:** **Most heat-sensitive vaccines** (in order of greatest sensitivity): 1. **OPV (Oral Polio Vaccine)** — extremely heat-sensitive; must be stored in the coldest part of the freezer at regional level and in the coldest area of the refrigerator at the health center 2. **Measles/MMR** — heat-sensitive; usually stored in the freezer at regional level and in the coldest part of the refrigerator at facility level 3. **BCG** — moderately heat-sensitive 4. **Pentavalent, DPT, Hepatitis B, Td** — relatively less heat-sensitive but still require refrigeration 5. **PCV** — relatively less heat-sensitive but requires refrigeration **Freeze-sensitive vaccines** (must NOT be frozen; freezing destroys potency): - **DPT, Pentavalent, Hepatitis B, Td vaccines** — These contain adsorbed antigens; freezing causes crystal formation and loss of efficacy - **The shake test (also called the vaccine vial monitor shake test or sterility test)** can detect if a freeze-sensitive vaccine has been frozen: a frozen vaccine will have visible ice crystals or unusual particles; when thawed, clumping may occur. Any vaccine suspected of freezing should not be used and should be reported to the supervisor for appropriate disposal and replacement. **Cold Chain Equipment and Maintenance:** - **Refrigerators at health centers:** Should be dedicated to vaccines only (or separated with vaccines in upper shelves/coldest sections); should have a door alarm and temperature monitoring device (thermometer or data logger); should be checked twice daily for temperature and logged; defrosting should be done monthly without removing vaccine vials - **Freezers at regional level:** Used for long-term storage of OPV and measles vaccines; must maintain −15°C to −25°C - **Ice packs and cool boxes:** Used for vaccine transport during outreach/vaccination campaigns; ice packs should be wrapped in newspaper or cloth (not direct contact with vaccine vials) to prevent freezing of freeze-sensitive vaccines - **Vaccine carriers:** Insulated bags used during community immunization clinics; lined with ice packs or frozen water bottles to maintain temperature for up to 8 hours **Vaccine Vial Monitor (VVM):** The **Vaccine Vial Monitor** is a small label affixed to vaccine vials that changes color in response to cumulative heat exposure. The VVM contains a heat-sensitive material that darkens over time as the vaccine is exposed to elevated temperatures. The label has a central square and a reference circle: - If the central square remains **lighter than the reference circle**, the vaccine is safe to use. - If the central square becomes **darker than or equal to the reference circle**, the vaccine has exceeded its heat exposure limit and should not be used (discard the vial). - The VVM helps identify vaccines that have been exposed to heat but may not show obvious physical changes, preventing the use of potency-compromised vaccines. **FEFO (First Expiry, First Out):** Vaccine stock should be rotated using the **FEFO principle**: vaccines with the earliest expiration dates are used first, regardless of when they were received. This prevents vaccine wastage due to expiration and ensures that older vaccines are not inadvertently shelved behind newer ones. FEFO applies to storage in refrigerators, freezers, and vaccine carriers. The nurse or health worker responsible for immunization clinics must check expiration dates and arrange vaccines accordingly. **Vaccine Storage at Health Centers: Practical Steps** 1. **Organize the refrigerator:** Keep vaccines in the coolest section (usually the lowest shelf or door-side shelves are warmer). OPV and measles should be in the coldest area; Hepatitis B, DPT, Pentavalent, and Td in slightly warmer sections (but still cold). 2. **Monitor temperature:** Check and record the refrigerator temperature twice daily (morning and afternoon). A thermometer or data logger provides accurate readings. Acceptable range: +2°C to +8°C. 3. **Do not overstock:** Avoid crowding the refrigerator, which impedes air circulation and causes uneven cooling. 4. **Do not store food or medicines alongside vaccines:** Only vaccines and water bottles (for thermal mass) should be stored in the vaccine refrigerator. 5. **Rotate stock by FEFO:** Organize by expiration date, placing vaccines with earlier expiration dates at the front. 6. **Check VVM on every vial before use:** Assess that the VVM is lighter than the reference circle; if not, discard the vial. 7. **Transport vaccines:** Use insulated vaccine carriers with frozen ice packs (wrapped to avoid direct contact with freeze-sensitive vaccines) for outreach clinics; maintain temperature for up to 8 hours. 8. **Report problems:** If the refrigerator breaks down, temperature logs show consistent temperature outside the range, or VVM indicates heat exposure, report immediately to the supervisor so corrective action (repair, replacement, or stock rotation) can be taken. The cold chain is not the responsibility of the nurse alone but of the entire health facility team. Facility managers, supervisors, and vaccine handlers all share accountability for maintaining vaccine potency through proper cold chain management.

Disease surveillance is the systematic, ongoing collection, analysis, and interpretation of disease data to guide public health action. The **Philippine Integrated Disease Surveillance and Response (PIDSR)** system is the official surveillance framework mandated by the Department of Health and is based on legislation including the **Philippine Health Code (RA 11700)** and various Executive Orders. Under PIDSR, certain diseases are classified as **notifiable**, meaning that healthcare providers (including nurses) have a legal and ethical obligation to report cases to the local health authority without delay. The purpose of notifiable disease reporting is to: - Enable rapid detection of outbreaks and unusual disease clusters - Trigger public health investigations and control measures (case isolation, contact tracing, disinfection) - Monitor disease trends and guide prevention and control resource allocation - Evaluate the effectiveness of public health interventions - Maintain epidemiological intelligence at local, national, and international levels Notifiable diseases are classified by **reporting urgency**: **Class 1: Immediately Notifiable (within 24 hours)** Diseases of epidemic potential, high mortality risk, or eradication/elimination targets must be reported **within 24 hours** by the quickest available means (telephone, text, immediate in-person report to local health authority): - **Acute Flaccid Paralysis (AFP) / Poliomyelitis** — a case of sudden paralysis in a child or any age is suspicious for polio until proven otherwise; immediate report may trigger immunization campaigns - **Measles** — a febrile illness with rash (characteristic 3-day cough–coryza–conjunctivitis prodrome) and risk of complications; outbreak response may include catch-up vaccination - **Neonatal Tetanus** — tetanus in a newborn (usually within first 2 weeks of life, presenting with poor feeding, inability to cry, muscle stiffness); indicates a gap in maternal tetanus immunization and triggers investigation of delivery and cord care practices - **Cholera** — acute diarrheal disease with severe dehydration; requires isolation, fluid replacement, and contact management - **Meningococcal Disease** — bacterial meningitis caused by *Neisseria meningitidis*; high mortality if untreated and risk of outbreaks in congregate settings; requires immediate isolation and prophylaxis of close contacts - **Rabies** — fatal viral disease; immediate post-exposure prophylaxis is time-critical and case reporting triggers investigation of animal source - **Dengue** (when severe: dengue hemorrhagic fever, dengue shock syndrome) — though dengue is weekly notifiable, severe dengue with warning signs is reportable urgently - Other epidemic-prone diseases depending on the epidemiological situation **Class 2: Weekly Notifiable** Routine conditions with moderate public health importance are reported **weekly** (usually every Monday or as per local health authority schedule): - **Dengue (non-severe)** — febrile illness with 2 or more of: headache, myalgia/arthralgia, rash, leukopenia; no warning signs - **Tuberculosis** — reported weekly by DOTS programs; allows tracking of case detection and treatment outcomes - **Typhoid Fever** — salmonella typhi infection; risk of outbreaks in areas with poor sanitation - **Diphtheria, Pertussis, Poliomyelitis (non-AFP)** — ongoing tracking of vaccine-preventable disease cases to assess EPI effectiveness - **Pneumonia** (severe community-acquired pneumonia in children) - **Hepatitis A, B, C** — tracks disease burden and identifies high-risk populations - **Sexually transmitted infections (STIs)** — syphilis, gonorrhea; public health importance for partner notification and screening - Other diseases depending on local epidemiology **Reporting Process:** The **nurse's responsibility** in disease surveillance includes: 1. **Recognize** — Know the signs/symptoms of notifiable diseases and maintain a high index of suspicion 2. **Report** — Immediately notify the physician, health officer, or local health authority (RHU or city/municipal health office) verbally or in writing, depending on urgency class 3. **Document** — Complete the Case Report Form (CRF) with patient demographics, clinical findings, diagnosis, and epidemiological information (exposure history, contacts, occupation) 4. **Collect specimens** — If the disease requires laboratory confirmation (e.g., TB sputum, measles serology, dengue IgM), assist in proper specimen collection and transport following standard precautions 5. **Implement infection control** — Isolate infectious cases appropriately (respiratory, droplet, or contact precautions as indicated by the disease) 6. **Follow up** — Participate in contact tracing, vaccination, and post-exposure prophylaxis as needed **Confidentiality:** While reporting is mandatory, patient confidentiality is maintained. Case reports contain minimal personal identifiers necessary for investigation; information is shared only with authorized public health officials. **Legislative Framework:** Under **RA 9173 (Philippine Nursing Act)**, nurses are mandated to perform surveillance and reporting as part of their community health nursing responsibilities. Failure to report notifiable diseases can result in disciplinary action and, more importantly, delays outbreak response and allows preventable disease to spread. **Examples of High-NLE-Yield Notifiable Diseases:** - **Measles:** Reported immediately because it spreads rapidly and has high mortality in young children; case detection may trigger outbreak response with vaccination campaigns in affected communities - **TB:** Reported weekly; DOTS programs track treatment adherence and outcomes - **Dengue:** Weekly reporting; DOH monitors dengue trends, issues weather-dependent warnings, and activates the 4-S strategy during high transmission seasons - **Poliomyelitis:** Any case of acute flaccid paralysis (AFP) is reported immediately as a suspected case until polio is ruled out; triggers immediate community immunization The nurse's role in surveillance is frontline and critical: early detection and reporting allow public health authorities to respond swiftly, interrupt transmission, and prevent epidemics.

Tuberculosis (TB) remains a significant public health challenge in the Philippines. According to recent DOH reports, the Philippines ranks among the countries with the highest TB burden. The **National TB Control Program (NTP)** implements the **DOTS (Directly Observed Treatment, Short-course)** strategy, an evidence-based, cost-effective approach endorsed by the WHO and adopted globally. The community nurse plays a pivotal role in TB control through case detection, directly observed therapy, patient support, and community education. **DOTS: The Five Pillars** The DOTS strategy comprises five essential elements: **1. Political Commitment with Sustained Financing** Government commitment ensures that TB control is prioritized in health budgets, human resources are allocated, and programs are sustained even when TB incidence declines. The Philippine government has declared TB a public health emergency and committed to the WHO's End TB Strategy targets. Without sustained financing, drug supplies are interrupted, health workers are not trained, and laboratories cannot function, leading to program collapse and resurgence of TB. **2. Case Detection Through Quality-Assured Bacteriology** Active case-finding and accurate diagnosis form the foundation of TB control. The primary diagnostic tools are: - **Xpert MTB/RIF (GeneXpert MTB/RIF):** A rapid automated molecular test that detects *Mycobacterium tuberculosis* DNA and simultaneously detects rifampicin-resistant TB (a marker for multidrug-resistant TB). Xpert MTB/RIF is now the **first-line diagnostic test** recommended by the WHO and the Philippine NTP. Results are available within 2 hours; the test is accurate, sensitive, and specific; and it can be performed at peripheral facilities with minimal training. Xpert MTB/RIF is particularly valuable for diagnosing TB in HIV-positive individuals and TB in children (where sputum smear may be negative). - **Direct Sputum Smear Microscopy (DSSM):** A conventional method using Ziehl-Neelsen or auramine-phenol staining to visualize acid-fast bacilli (AFB) in sputum smears under microscopy. DSSM is less expensive than Xpert MTB/RIF and remains in use in resource-limited settings. However, DSSM is less sensitive (requires ~5,000–10,000 bacilli per mL of sputum) and does not detect drug resistance. DSSM is still used for **treatment monitoring** (repeat sputum smears at defined intervals during treatment to confirm bacterial clearance). - **Chest X-ray:** Supports TB diagnosis, especially in smear-negative or extrapulmonary TB, but is not a stand-alone diagnostic tool. - **TB culture:** Gold standard for TB diagnosis but requires 2–8 weeks and is not practical for routine diagnosis. Used mainly in cases of suspected drug-resistant TB or when diagnosis is uncertain. Sputum specimen collection is typically done via **spot–morning–spot method** (one spot sample on the first visit, an early morning sample collected by the patient at home, and another spot sample on the next clinic visit), or **spot–spot** (two spot samples at two separate clinic visits), depending on the NTP protocol and resource availability. **3. Standardised Treatment Regimen with Direct Observation** The hallmark of DOTS is **direct observation:** a trained health worker, community health worker, treatment partner (family member), or pharmacist watches the patient ingest each dose of anti-TB medication. Direct observation ensures adherence, allows assessment of side effects in real-time, and provides an opportunity for patient education. **Missing doses is the most common reason for treatment failure and the genesis of drug-resistant TB.** **First-line anti-TB drugs:** - **H = Isoniazid** (INH) - **R = Rifampicin** (RIF) - **Z = Pyrazinamide** (PZA) - **E = Ethambutol** (EMB) - **S = Streptomycin** (SM) — used in Category II regimens These drugs are combined in fixed-dose combinations (FDCs) to simplify dosing and reduce pill burden. **Treatment phases and regimens:** - **Intensive Phase (~2 months):** Frequent dosing to rapidly reduce bacterial load and render the patient non-infectious. - **Continuation Phase (~4 months):** Longer-duration therapy to prevent relapse by sterilizing the lungs and eliminating dormant bacilli. **Category I (New TB cases):** New smear-positive pulmonary TB, new smear-negative pulmonary TB, or any extrapulmonary TB - **Regimen: 2HRZE / 4HR** - Intensive phase: 2 months of **H + R + Z + E** daily - Continuation phase: 4 months of **H + R** daily - **Total duration: 6 months** - **Daily supervised doses:** 60 doses in intensive phase + 120 doses in continuation phase = 180 doses total **Category II (Previously treated TB cases):** Relapse, treatment after failure, treatment after lost to follow-up, or treatment after default - **Regimen: 2HRZES / 1HRZE / 5HRE** (older regimen) or **2HRZES / 4HR** (simplified, where available) - Intensive phase: 2 months of **H + R + Z + E + S** daily (SM provides additional coverage for resistant organisms) - A transition month with **H + R + Z + E** - Continuation phase: 5 months of **H + R + E** (or 4 months **H + R** in simplified regimens) - **Total duration: 8 months** - Higher risk of drug resistance; longer and more complex regimen **Drug-resistant TB (MDR-TB and XDR-TB):** - **Multidrug-resistant TB (MDR-TB):** Resistance to at least both isoniazid and rifampicin - **Extensively drug-resistant TB (XDR-TB):** MDR-TB plus resistance to fluoroquinolones and injectable second-line drugs - Managed under the **Programmatic Management of Drug-Resistant TB (PMDT)** with longer regimens (18–20 months), more toxic drugs (fluoroquinolones, injectable agents, newer agents like bedaquiline), and higher rates of adverse effects and mortality **4. Uninterrupted Supply of Quality-Assured Anti-TB Drugs** Drug stockouts, substandard drugs, or counterfeit drugs are catastrophic for TB control. The NTP ensures: - Central procurement of TB drugs via the DOH - Quarterly forecasting and ordering based on case detection rates - Regular stock monitoring at health facilities to prevent stockouts - Quality assurance: all drugs are WHO-pre-qualified or approved by regulatory agencies - Safe storage: drugs are kept in cool, dry conditions away from light - FEFO rotation to prevent expiration and wastage **5. Standardised Recording and Reporting System** Every TB patient is registered in a TB register with unique identification number. Data recorded include: - Patient demographics and contact information - TB classification (pulmonary smear-positive, smear-negative, extrapulmonary) - HIV status - Sputum results and Xpert MTB/RIF results - Treatment start date, doses taken (documented by health worker who observed each dose), and any periods of default - Side effects and actions taken - **Treatment outcomes:** - **Cured:** Completed treatment with negative sputum smear at end of treatment and at least one previous occasion - **Treatment completed:** Completed full treatment course but without bacteriological confirmation of cure - **Treatment failed:** Sputum remains positive after 5 months of treatment or converts from negative to positive (indicates drug resistance) - **Lost to follow-up:** Patient absent from treatment for ≥2 consecutive months - **Died:** From any cause Data from TB registers are compiled quarterly and reported to district, provincial, and national TB programs. This reporting system allows real-time monitoring of case detection and treatment outcomes, enabling program managers to identify gaps and implement corrective actions. **Nursing Responsibilities in TB Control:** **Case Detection and Diagnosis:** - Identify TB suspects (anyone with cough for ≥2–3 weeks, regardless of other symptoms) - Educate communities about TB symptoms and the importance of early health-seeking - Assist in sputum specimen collection and ensure proper transport to the laboratory - Communicate results to patients and health workers promptly **Direct Observation of Therapy (DOT):** - **The core responsibility:** Observe the patient swallowing every dose of anti-TB medication - Administer DOT at a designated venue (health facility, school, workplace, or patient's home) - Maintain a treatment card or register documenting each observed dose - If DOT cannot be provided by a health worker (e.g., in very rural areas or patient preference), identify and train a reliable **treatment partner** (family member, teacher, employer) to directly observe doses; the health worker maintains supervision and spot-checks - Address any missed doses immediately by counseling and re-engagement **Patient Education:** - Explain TB transmission (airborne droplets, cough etiquette, ventilation) - Emphasize the importance of completing the full 6-month (Category I) or 8-month (Category II) course - Teach that stopping early causes drug resistance, making TB harder and more expensive to treat - Provide written information in the local language **Side Effect Monitoring:** - **Isoniazid (H):** Peripheral neuropathy (tingling in fingers/toes); peripheral neuropathy is preventable with vitamin B6 supplementation - **Rifampicin (R):** Orange-red discoloration of urine, sweat, and tears; this is harmless and expected; warn patients to expect this to prevent alarm and discontinuation - **Pyrazinamide (Z):** Hyperuricemia (elevated uric acid) causing gout-like joint pain; hyperuricemia is usually asymptomatic - **Ethambutol (E):** Optic neuritis causing color blindness (red-green) and vision loss; baseline vision assessment and monthly monitoring are essential; patients report any vision changes immediately - **Streptomycin (S):** Ototoxicity (hearing loss and vertigo); baseline and periodic audiometry in patients on SM - **Hepatotoxicity:** All first-line drugs can cause liver injury; baseline liver function tests and monthly monitoring are recommended, especially in patients with pre-existing liver disease or HIV Any serious side effect warrants contact with the TB program supervisor and possible regimen adjustment. **Contact Tracing:** - Identify household and close contacts of the TB patient - Screen contacts for TB symptoms - Refer symptomatic contacts for diagnostic evaluation - For asymptomatic child contacts (especially <5 years), assess for TB infection via tuberculin skin test (TST) or interferon-gamma release assay (IGRA); TB-infected children without active disease benefit from **TB preventive therapy (TPT)** (isoniazid monotherapy for 6 months) **TB/HIV Collaboration:** - Patients with TB should be tested for HIV; if HIV-positive, anti-TB and antiretroviral therapy (ART) are coordinated - TB preventive therapy (TPT) is offered to all HIV-positive individuals to reduce TB risk **Community Education:** - Teach cough etiquette: cover mouth when coughing, use handkerchief, avoid spitting - Promote ventilation in homes and workplaces (open windows) - Dispel myths and stigma: TB is curable with treatment; treatment does not make one infertile - Encourage TB-related health-seeking behavior **Infection Control:** - Place TB-suspected or confirmed patients on respiratory isolation (separate room with ventilation) during the first 2 weeks of treatment (infectious period) - Use standard precautions (hand hygiene, safe injection practices) - Health workers with cough symptoms should be tested for TB promptly **Follow-up and Support:** - Home visits to monitor adherence and address barriers (e.g., transportation, side effects, poverty, alcohol use) - Nutritional support and counseling (TB patients have increased nutritional needs during recovery) - Address comorbidities (diabetes, chronic kidney disease, malnutrition) that complicate TB - Celebrate milestones (completing intensive phase, sputum conversion) to motivate continuation of treatment **Indicators of Successful DOTS Implementation:** - High case detection rate (case detection rate = number of diagnosed TB cases / estimated TB cases × 100; target ≥90%) - High treatment success rate (cure + treatment completed / total cases registered × 100; target ≥90%) - Low default/lost to follow-up rate (target <5%) - Low treatment failure rate (target <3%) - Low mortality rate (target <5%) These indicators demonstrate that the DOTS strategy is working and that TB is being diagnosed, treated effectively, and cured in the community.

Dengue is a mosquito-borne viral disease endemic in the Philippines and a major cause of morbidity and mortality, particularly in children. The disease is transmitted by the **Aedes aegypti** mosquito (and less commonly by Aedes albopictus). Unlike malaria or filariasis, dengue is an **urban and peri-urban disease**, thriving in areas with poor sanitation, water storage practices, and solid waste management. Community nurses play a critical role in dengue prevention, surveillance, and case management. **The Dengue Vector: Aedes aegypti** - **Appearance:** Small, dark mosquito with white markings (stripes) on the body and legs; easily distinguished from other mosquitoes - **Habitat:** Breeds in **clean, stagnant water**—not in dirty water or natural water bodies. Common breeding sites include water storage containers (drums, tanks, buckets, jars), flower pots and plant saucers, clogged gutters, discarded tires, coconut shells, and any receptacle that collects rainwater or household water. This is critical to understand: dengue control focuses on eliminating artificial water containers, not natural water sources like ponds or rivers. - **Biting behavior:** **Day-biter** (active during daylight hours, especially in early morning and late afternoon); not a night-biter like malaria mosquitoes. This has implications for prevention: insecticide-treated bed nets are less effective for dengue; instead, repellent use and protective clothing during the day are emphasized. - **Flight range:** Flies short distances, typically within 100 meters of breeding site; does not travel long distances; dengue clusters are usually localized to neighborhoods where breeding sites exist - **Lifespan:** Adults live 2–3 weeks; aquatic larvae develop in 7–10 days in warm water; the rapid life cycle allows quick population recovery if control measures are relaxed **Dengue Virus and Serotypes** - There are **four dengue serotypes (DENV-1, DENV-2, DENV-3, DENV-4)** - Infection with one serotype provides **lifelong immunity to that serotype** (homologous immunity) - However, immunity to other serotypes is **temporary** (2–3 months); after this period, a person is susceptible to the other three serotypes - **Antibody-dependent enhancement (ADE):** A second dengue infection (with a different serotype) is more likely to cause **severe dengue** (dengue hemorrhagic fever [DHF] or dengue shock syndrome [DSS]) than the primary infection. This is because non-neutralizing antibodies from the first infection bind to the virus but do not prevent entry; instead, they facilitate entry into mononuclear cells via Fc receptors, leading to higher viral replication and more severe immune response. This phenomenon is crucial to understanding dengue epidemiology: in areas with multiple circulating serotypes, sequential dengue infections pose a higher risk of severe dengue. **Clinical Presentation** **Dengue Fever (DF):** Classic presentation - **Incubation:** 3–14 days (average 5–6 days) after mosquito bite - **Onset:** Abrupt fever (often very high, 39–40°C or higher), severe headache, myalgia (body aches), arthralgia (joint pain), retro-orbital pain (pain behind the eyes, characteristic of dengue) - **Rash:** Appears 3–4 days into illness, usually after fever begins to subside; maculopapular or maculovesicular rash on trunk and extensor surfaces; may spare palms and soles - **Duration:** Fever lasts 5–7 days; overall illness resolves within 1–2 weeks - **Lab findings:** Leukopenia (low white blood cell count), thrombocytopenia (low platelets), elevated liver enzymes (AST, ALT) - Prognosis: Most patients recover fully without sequelae **Severe Dengue (previously called dengue hemorrhagic fever [DHF] or dengue shock syndrome [DSS]):** Severe dengue is characterized by increased vascular permeability, plasma leakage, and hemorrhagic manifestations. Risk factors include: - Secondary dengue infection (2nd infection with different serotype) - Female sex - Age >30 years (some data suggest) - Infants born to dengue-immune mothers - Dengue with warning signs (see below) that are not managed **Warning signs** that predict progression to severe dengue (appear around day 3–5, often as fever subsides): - **Severe abdominal pain** - **Persistent vomiting** - **Bleeding** (spontaneous bleeding from gums, nose; blood in vomit, stool, urine; petechiae on skin) - **Lethargy, restlessness, or change in mental status** - **Rapid drop in platelet count** (on repeat labs) Any patient with dengue and warning signs should be managed in a hospital setting with IV fluid therapy, monitoring of vital signs and urine output, and repeat laboratory testing. The critical phase lasts 24–48 hours; if the patient survives this phase with appropriate fluid management, prognosis is generally good. **Severe dengue manifestations:** - **Dengue hemorrhagic fever (DHF):** Plasma leakage with hemorrhagic manifestations, thrombocytopenia (<100,000/μL), hematocrit increase ≥20% - **Dengue shock syndrome (DSS):** Severe plasma leakage causing shock (hypotension, prolonged capillary refill, cold extremities, altered mental status); mortality can reach 5–10% with appropriate treatment, higher without - **Dengue with organ involvement:** Severe hepatitis, acute kidney injury, encephalitis, myocarditis **Diagnosis** - **Rapid diagnostic tests (RDTs):** Detect dengue IgM (primary infection) or IgG (past infection); available at health centers; results within 15–30 minutes - **NS1 antigen test:** Detects dengue non-structural protein 1; positive in the first 5 days of illness; more specific than RDT - **RT-PCR (reverse transcription polymerase chain reaction):** Detects dengue RNA; gold standard; available in reference laboratories; used for confirmation and serotype identification - **Serological testing (paired sera):** IgM and IgG titers 4-fold rise between acute and convalescent sera; confirms dengue **DOH "4-S Strategy" Against Dengue** The Department of Health 4-S strategy is a comprehensive, community-based approach to dengue control emphasizing prevention and early management: **1. Search and Destroy (Source Reduction)** **Goal:** Eliminate Aedes breeding sites in the community **Community-level interventions:** - **Community mobilization:** Organize monthly, weekly, or even daily (depending on season) community "Search and Destroy" campaigns - **Inspection of households:** Community health workers and volunteers inspect water storage containers, ask residents to empty containers or cover them with lids or cloth - **Proper water storage:** Encourage residents to store water in covered containers (drums, tanks with lids); water left in open containers is a prime breeding site - **Solid waste management:** Remove discarded tires, bottles, cans, and other trash that can collect rainwater - **Environmental modification:** Improve water drainage (e.g., clear clogged gutters), fill low-lying areas that collect water - **Community cleanliness:** Regular cleaning of surroundings to remove debris - **School participation:** Include dengue vector control in school waste management and cleanliness programs - **Workplace inspection:** Inspect factories, offices, markets for breeding sites Community participation is essential; dengue control is a collective responsibility, not solely a government task. **2. Self-Protection (Individual Protection Measures)** **Goal:** Prevent Aedes mosquito bites **Personal protection methods:** - **Insect repellent:** Apply mosquito repellent (DEET 10–30%, picaridin, or natural repellents like lemongrass oil) to exposed skin, especially during daytime hours (5 AM–9 PM when Aedes is most active). Reapply as directed on the product label. - **Long-sleeved clothing:** Wear long sleeves and long pants, especially outdoors during daytime - **Screens and netting:** Use window screens and door screens in homes to prevent mosquito entry; bed nets (though less effective than for malaria) can provide additional protection - **Air conditioning:** Aedes activity is reduced in cool, air-conditioned spaces - **Stay indoors during peak biting hours:** If possible, minimize outdoor activity during early morning and late afternoon when Aedes bites most aggressively **3. Seek Early Consultation (Health-Seeking Behavior)** **Goal:** Early detection and prompt treatment to prevent severe dengue **Community education on warning signs:** The nurse educates the community on dengue fever signs (fever, headache, body aches, rash) and **critical warning signs** (severe abdominal pain, persistent vomiting, bleeding, lethargy, restlessness) that indicate dengue is progressing to severe form. **Message:** "If you have dengue fever and notice warning signs, go to the hospital immediately. Severe dengue can be life-threatening if not treated, but with prompt IV fluids and medical care, most patients survive." **Encourage reporting:** Community members report suspected dengue cases to the health center for testing and registration (part of weekly disease surveillance). **Home management of dengue fever** (for non-severe cases): - **Rest and hydration:** Increase fluid intake (water, electrolyte drinks, fruit juices) to prevent dehydration - **Fever management:** Acetaminophen or paracetamol (avoid aspirin and NSAIDs because they increase bleeding risk in dengue) - **Monitor for warning signs:** Watch for severe abdominal pain, vomiting, bleeding, or mental status changes; if any warning sign appears, seek medical care immediately - **Follow-up:** Return to health center or hospital for repeat laboratory tests (platelets, hematocrit) to monitor disease progression **4. Support Fogging and Spraying During Outbreaks** (in hotspot areas) **Goal:** Reduce adult mosquito population during high-transmission periods **Context:** Vector control insecticides (space spraying, residual spraying) are used during dengue outbreaks to rapidly reduce adult mosquito populations. However, fogging is expensive, has limited durability (mosquito populations recover within 2–3 weeks), and should be used judiciously only in outbreak situations or high-risk areas. **Nurse's role:** - Educate the community on the need for fogging during outbreaks - Inform residents of scheduled fogging and precautions (stay indoors during spraying, ventilate homes afterward, protect food and water) - Support community participation in fogging activities - Emphasize that fogging is a **temporary measure** and must be combined with sustained source reduction (4-S 1, 2, 3) for long-term control **Current Evidence:** Research shows that fogging alone is **not effective** for sustained dengue control; it provides only temporary mosquito suppression. The most effective strategy combines source reduction (elimination of breeding sites), community participation, and early case detection. **Nurse's Role in Dengue Control** - **Community education:** Teach dengue transmission, warning signs, and the 4-S strategy in community talks, barangay meetings, schools - **Source reduction campaigns:** Lead or participate in community dengue inspections and cleanup activities - **Case detection and testing:** Screen patients with fever for dengue; collect blood samples for rapid dengue testing or confirmation tests - **Case management:** Provide counseling, educate on warning signs, and refer severe cases promptly to hospitals - **Surveillance:** Report dengue cases weekly to the health information system; monitor dengue trends in the community - **Data analysis:** Identify dengue hotspots and high-risk areas for targeted interventions - **Community mobilization:** Engage barangay officials, schools, workplaces in dengue control activities - **Advocacy:** Advocate for sustained funding, human resources, and political commitment to dengue control **Seasonal Considerations:** Dengue transmission is influenced by rainfall and temperature. In the Philippines: - **Rainy season (June–November):** Increased breeding sites due to rainwater accumulation; dengue incidence peaks - **Dry season (December–May):** Fewer breeding sites; dengue incidence lower but still present The DOH issues seasonal dengue alerts and may activate intensified surveillance and control activities during predicted high-transmission periods.

While TB, dengue, and vaccine-preventable diseases dominate the NLE, several other communicable diseases remain endemic in the Philippines and may appear in NLE questions, especially in scenario-based items. Each has distinct epidemiology, transmission, and control strategies that community nurses must understand. **Malaria: Parasitic Disease Transmitted by Anopheles Mosquitoes** **Agent:** Plasmodium parasites (*P. falciparum, P. vivax, P. malariae, P. ovale*); transmitted by female Anopheles mosquitoes **Epidemiology:** - Malaria is **endemic in specific regions of the Philippines**, particularly in Mindanao, Palawan, and some parts of the Visayas; NOT nationwide - **Night-biting mosquito** (unlike dengue's day-biting Aedes); females feed at night to obtain blood meal for egg production - Transmission requires the parasite to complete a development cycle in the mosquito (7–10 days); hence, malaria is a vector-borne disease but with longer incubation and different biology than dengue - **Altitude:** Anopheles breeds in natural water bodies at lower altitudes; malaria is rare at high altitudes **Clinical Presentation:** - Incubation: 10–30 days (varies by Plasmodium species) - Fever pattern: Classical "tertian" (every 3 days) or "quartan" (every 4 days) fever; intermittent spikes with chills and sweats - Associated symptoms: Headache, myalgia, weakness, jaundice (especially in *P. falciparum*) - Severe malaria: Cerebral malaria, acute kidney injury, pulmonary edema, severe anemia - Untreated or improperly treated, malaria can be fatal **Diagnosis:** Blood smear microscopy (thick and thin films stained with Giemsa) shows parasites; rapid diagnostic tests (RDTs) for malaria antigen are available **Prevention and Control:** - **Insecticide-treated bed nets (ITNs):** Effective because Anopheles is a night-biter; nets are impregnated with long-lasting insecticide (e.g., pyrethroids); provide both mechanical barrier and insecticidal effect - **Indoor residual spraying (IRS):** Spray homes with insecticide to kill resting mosquitoes - **Personal protection:** Long sleeves and pants in the evening and at night - **Case detection and prompt treatment:** Early diagnosis and treatment of malaria cases reduce transmission and prevent complications - **Vector control:** Larval control in breeding habitats (natural water bodies), environmental management **Nurse's role:** Case detection, diagnosis confirmation, patient education on ITN use and adherence to antimalarial treatment, contact tracing and community surveillance in endemic areas, health education about malaria risks and prevention in high-risk regions **Schistosomiasis (Bilharzia)** **Agent:** *Schistosoma japonicum*; parasitic flatworm **Intermediate host:** Oncomelania snails; eggs in human feces contaminate water; miracidia (larvae) penetrate snails; cercariae (infectious larvae) are released from snails into water **Transmission:** Humans become infected by contact with water containing cercariae (swimming, wading, fishing, bathing in contaminated water) **Endemic areas:** Specific regions in the **Visayas (Samar, Leyte, Bohol) and parts of Mindanao**; not nationwide; recent resurgence in some areas **Clinical presentation:** - **Acute schistosomiasis:** Swimmer's itch (itching at the site of cercarial penetration), fever, cough, abdominal pain (occurs 2–4 weeks after infection) - **Chronic schistosomiasis:** Abdominal pain, diarrhea, dysentery (bloody stools), hepatomegaly, splenomegaly, malnutrition, anemia, growth retardation in children **Diagnosis:** Stool microscopy detects eggs (diagnostic); serological tests **Prevention and Control:** - **Safe water supply:** Provide piped, treated water to reduce need for contact with contaminated water - **Sanitation:** Install latrines to prevent fecal contamination of water - **Health education:** Teach communities about transmission, avoid contaminated water, maintain hygiene - **Snail control:** Chemical treatment of water bodies to eliminate Oncomelania snails (less feasible in endemic areas with many water bodies) - **Mass drug administration (MDA):** Periodic treatment of at-risk populations (schoolchildren, endemic communities) with praziquantel - **Environmental modification:** Reduce snail habitats by water resource management **Nurse's role:** Community education, screening in endemic areas, support of mass drug administration campaigns, health education on safe water and sanitation **Lymphatic Filariasis (Elephantiasis)** **Agent:** Parasitic nematodes (*Wuchereria bancrofti, Brugia malayi, Brugia timori*); transmitted by Culex, Anopheles, or Aedes mosquitoes depending on species and region **Transmission:** Infected mosquitoes inject larval parasites; larvae develop into adult worms in lymphatic vessels and lymph nodes; microfilariae (tiny larvae) circulate in blood and are taken up by mosquitoes, perpetuating transmission **Endemic areas:** Various regions in the Philippines; incidence is decreasing due to elimination programs **Clinical presentation:** - **Acute phase:** Lymphangitis (inflammation of lymph vessels), lymphadenitis, fever, pain - **Chronic phase:** Lymphedema (swelling of limbs, genitals) due to lymphatic obstruction; elephantiasis (severe swelling and thickening of skin and subcutaneous tissue in limbs, genitals, or breasts) - Massive psychosocial impact due to disfigurement and disability **Diagnosis:** Blood microscopy detects microfilariae (nocturnal periodicity in some species; blood draw at night may be required); serology **Prevention and Control:** - **Mass drug administration (MDA):** Annual or biannual treatment of entire endemic populations with anthelmintics (diethylcarbamazine [DEC], ivermectin) to reduce microfilaremia and block transmission - **Vector control:** Mosquito control measures (bed nets, insecticide spraying) in areas where filariasis is endemic - **Case management:** Treat symptomatic patients; manage lymphedema through limb elevation, compression, skin care - **Health education:** Community awareness of filariasis transmission and importance of MDA compliance **Elimination Status:** The Philippines has made significant progress in lymphatic filariasis elimination; many areas have achieved elimination, while others continue surveillance and MDA. **Nurse's role:** Community mobilization for MDA, health education, case detection and management, surveillance **Leprosy (Hansen's Disease)** **Agent:** *Mycobacterium leprae*; bacterium that affects skin and peripheral nerves **Transmission:** Prolonged contact with untreated cases; respiratory droplets; requires close, repeated contact for transmission **Endemic areas:** Leprosy persists in some regions of the Philippines, though incidence is declining; not all areas are equally affected **Clinical presentation:** - **Tuberculoid leprosy:** Few skin lesions (1–5), well-demarcated, minimal sensory loss; low bacterial load; resistant form - **Lepromatous leprosy:** Many (>5) ill-defined skin lesions, diffuse infiltration, high bacterial load; progressive form if untreated - **Borderline leprosy:** Intermediate presentations - **Complications:** Nerve damage leading to sensory loss and motor weakness (especially in hands and feet), claw hand deformity, ulceration and tissue loss, facial involvement, blindness - **Reactions:** Type 1 (delayed hypersensitivity) and Type 2 (erythema nodosum leprosum [ENL], immune complex); can occur during treatment and must be managed to prevent nerve damage **Diagnosis:** Clinical examination (skin lesions, sensory testing, nerve palpation); slit-skin smear microscopy; PCR **Prevention and Control:** - **Early case detection:** Health education and community screening to identify cases; many cases are undetected (hidden cases) due to stigma - **Multi-drug therapy (MDT):** WHO-recommended regimen (combination of rifampicin, dapsone, clofazimine) effective in all forms; treatment is curative - **Chemoprophylaxis:** Single-dose rifampicin given to contacts of leprosy cases reduces transmission risk - **Elimination:** The Philippines has achieved leprosy elimination as a public health problem (prevalence <1 per 10,000 population) but continues elimination of transmission (target <0.1 per 10,000) **Stigma and Rehabilitation:** - Leprosy carries significant social stigma; patients often delay diagnosis due to fear of ostracization - Psychosocial support, community education to reduce stigma, and rehabilitation programs (occupational therapy for hand deformities, support for livelihood) are critical **Nurse's role:** Stigma reduction through community education, early case detection, patient counseling, directly observed therapy for MDT, contact chemoprophylaxis, rehabilitation and livelihood support, monitoring for leprosy reactions **Rabies: Fatal Virus Transmitted by Animal Bites** **Agent:** Rabies virus; typically transmitted by saliva of infected animals **Transmission:** Bite or scratch from infected animal (dogs, cats, bats, wild animals); virus travels along nerves to the brain; incubation 1–3 months (can be longer) **Epidemiology:** - **Dog-mediated rabies is the most common source** in the Philippines - Once clinical symptoms appear, rabies is nearly 100% fatal; almost all humans who develop rabies encephalitis die - Post-exposure prophylaxis (PEP) is **highly effective** if given promptly (within 24 hours, ideally within hours of exposure) **Clinical presentation:** - **Prodromal phase:** Fever, tingling at bite site, anxiety, irritability - **Neurological phase:** Hydrophobia (fear of water; difficulty swallowing), aerophobia (fear of air), hypersalivation, hallucinations, aggression, paralysis - **Coma and death:** Usually within 7–10 days of symptom onset **Prevention:** - **Animal bite wound care:** Immediately after a suspected rabies exposure (bite from unknown or potentially rabid animal): - Wash wound vigorously with soap and running water for 15 minutes (mechanical removal of virus) - Apply antiseptic (iodine solution, chlorhexidine) - Do NOT suture the wound (unless absolutely necessary for cosmetic/functional reasons); if suturing is done, rabies immunoglobulin (RIG) should be infiltrated around the wound - **Post-exposure prophylaxis (PEP):** Combination of rabies vaccine and rabies immunoglobulin (RIG) - **Rabies vaccine:** WHO-approved schedules include Essen regimen (5 doses: day 0, 3, 7, 14, 28) or Zagreb regimen (4 doses on day 0, then schedule varies). Vaccine is given intramuscularly (deltoid for adults, anterolateral thigh for infants) - **Rabies immunoglobulin (RIG):** Human RIG (HRIG) or equine RIG (ERIG); given once at the time of exposure to provide immediate passive immunity while the vaccine stimulates active immunity. RIG should be infiltrated at the wound site; any remaining dose is given intramuscularly - PEP regimens vary by exposure category (category I: no exposure; category II: minor bite/scratch; category III: deep bite/mucous membrane exposure); PEP is indicated for category II and III exposures - **Timing:** PEP should begin as soon as possible after exposure; effectiveness decreases with delay; however, even if initiated >24 hours after exposure, PEP may still be beneficial - **Cost and availability:** Rabies vaccines and RIG are expensive and often in short supply in resource-limited settings; this is a major barrier to PEP in low-income regions - **Animal control:** Vaccination of dogs against rabies; management of stray dogs; education about avoiding contact with wild animals and bats **Nurse's role:** - **Immediate wound care:** Clean and disinfect bite wounds; assess bite category (superficial vs. deep, single vs. multiple) - **PEP coordination:** Refer patients for rabies vaccine and immunoglobulin; ensure compliance with full schedule - **Community education:** Teach what to do after an animal bite (seek care immediately); educate about dog vaccination; discourage approaching unknown animals - **Advocacy:** Advocate for rabies vaccine and RIG availability and affordability in health facilities **High-NLE-Yield Takeaway on Rabies:** Any patient bitten by an animal with unknown rabies status should receive **immediate wound care (soap and water, antiseptic) and post-exposure prophylaxis (vaccine + immunoglobulin) as soon as possible**. Delay in PEP can result in a preventable death. Community nurses must recognize animal bites as a medical emergency. **Integration with Community Nursing Practice** While malaria, schistosomiasis, filariasis, leprosy, and rabies may not be as frequently tested as TB and dengue, they are important in specific geographic and epidemiological contexts. Nurses working in endemic areas must be knowledgeable about case detection, early referral, and community prevention strategies. National elimination programs for leprosy and lymphatic filariasis have reduced the disease burden, but vigilance and support of MDA and case detection campaigns are ongoing. Rabies is a reminder that prompt post-exposure care can be lifesaving. **NLE Strategy:** For these diseases, focus on: - **Epidemiology and endemic areas** (which regions are affected) - **Prevention and control strategies** (vector control, case detection, MDA, PEP) - **Nurse responsibilities** in disease control programs - **High-risk exposures** (animal bites → rabies PEP; swimming in contaminated water → schistosomiasis prevention)

Communicable disease control represents one of the highest-impact, most heavily tested areas of the Philippine Nursing Licensure Examination. The preceding chapters have covered the foundational concepts (three levels of prevention, immunity), the flagship programs (EPI, TB control with DOTS, dengue control with 4-S), disease surveillance and reporting (PIDSR), and endemic disease-specific strategies. This summary section integrates these themes and highlights the essential role of the community nurse in communicable disease control under the Philippine Nursing Act (RA 9173) and the Philippine healthcare delivery system. **The Nursing Process Applied to Communicable Disease Control** Communicable disease control follows the nursing process: 1. **Assessment:** Community assessment identifies health risks (disease burden, endemic diseases, vulnerable populations), existing disease cases, immunization coverage, water and sanitation infrastructure, community knowledge and practices. Data collection includes epidemiological surveys, disease surveillance reports, health facility records, and community interviews. 2. **Diagnosis:** Using community health nursing diagnoses aligned with NANDA taxonomy and Maslow's hierarchy, the nurse identifies health problems (e.g., "Risk for measles transmission related to low immunization coverage as evidenced by 78% FIC rate in the barangay"; "Ineffective community health maintenance related to inadequate knowledge of dengue transmission as evidenced by multiple water containers in households"). These diagnoses guide intervention priorities. 3. **Planning:** Goals are set at three levels: - **Primary prevention:** Increase immunization coverage to >95%, reduce dengue vector breeding sites through community mobilization - **Secondary prevention:** Strengthen case detection (TB, dengue, measles) through active surveillance and health facility strengthening - **Tertiary prevention:** Improve TB treatment completion, manage dengue complications, support rehabilitation for sequelae of communicable diseases 4. **Implementation:** Interventions are tailored to the community and disease context: - **Health education:** Community talks, school programs, household counseling on disease transmission, prevention, and early care-seeking - **Immunization programs:** Vaccination clinics, home-based immunization for unreached populations, catch-up campaigns - **Case detection and management:** Active surveillance, facility-based case finding, DOTS provision for TB, case investigation - **Environmental health:** Community mobilization for water/sanitation improvement, vector control, safe food handling - **Advocacy:** Lobby for program funding, vaccine supply, equipment, and political commitment 5. **Evaluation:** Monitoring and evaluation assess program effectiveness: - **Coverage indicators:** % FIC, % children with BCG scar, TB case detection rate, dengue reporting rate - **Outcome indicators:** TB treatment success rate, dengue severe form prevention, absence of neonatal tetanus - **Process indicators:** Immunization clinic attendance, DOTS session attendance, contact tracing completion - **Impact indicators:** Morbidity and mortality reduction in target diseases Data are analyzed quarterly, reported to health authorities, and used to guide program adjustments and resource reallocation. **Integration with Maslow's Hierarchy of Needs** Communicable disease control addresses multiple levels of Maslow's hierarchy: - **Physiological needs:** Vaccination prevents life-threatening diseases and supports child survival; water and sanitation improvements provide safe water (basic physiological need) - **Safety needs:** Disease control, immunization, and environmental sanitation provide security from preventable disease; DOTS ensures patient safety through directly observed therapy - **Love and belonging:** Community mobilization and support groups (e.g., TB support groups, dengue survivor networks) address psychosocial needs; stigma reduction for leprosy and TB promotes social reintegration - **Esteem and self-actualization:** Community health workers and volunteer programs empower residents to participate in disease control, building self-efficacy and community ownership **Ethical Principles in Communicable Disease Control** - **Autonomy:** Vaccine information should be clear and uncoerced; parents make informed decisions about their children's immunization - **Beneficence:** Interventions aim to maximize benefit (herd immunity, TB cure, dengue prevention) - **Non-maleficence:** Minimize harm (vaccine adverse effects are monitored; cold chain integrity prevents ineffective vaccines) - **Justice:** Equitable access to vaccines and TB treatment regardless of ability to pay (RA 10152 mandates free vaccines; NTP provides free TB treatment); vulnerable groups (infants, pregnant women, poor) are prioritized - **Confidentiality and trust:** Disease reports are confidential; surveillance data are protected; trust in health systems is essential for reporting and early care-seeking **Barriers to Communicable Disease Control in the Philippine Context** The community nurse must navigate real-world barriers: - **Geographic barriers:** Remote or island communities have limited access to vaccines and health services; the nurse may need to conduct outreach immunization clinics - **Economic barriers:** Families may prioritize immediate food security over vaccination; transportation to TB treatment sites is costly; dengue prevention requires resources for water storage containers - **Educational barriers:** Low health literacy; misconceptions about vaccines and diseases; language barriers in multilingual communities - **Healthcare system barriers:** Vaccine and drug stockouts; inadequate cold chain equipment; staffing shortages; limited laboratory capacity - **Cultural and social barriers:** Traditional beliefs about disease etiology; stigma associated with TB and leprosy; gender-based barriers to healthcare access - **Environmental barriers:** Poor water and sanitation; vector-conducive environments; climate change exacerbating dengue transmission The community nurse advocates for resource mobilization and implements culturally sensitive, contextually appropriate interventions to overcome these barriers. **High-Yield NLE Concepts: Final Review** **On Primary Prevention and Immunization:** - EPI launched 1976; RA 10152 (2011) mandates free vaccines and Hep B within 24 hours of birth - 6–10–14 weeks: Pentavalent, OPV, PCV (3 doses each) - BCG at birth (0.05 mL intradermal); measles MCV1 at 9 months, MMR at 12 months (subcutaneous) - Fully Immunized Child (FIC): 1 BCG + 3 OPV + 3 Pentavalent + ≥1 measles before 12 months - Cold chain: +2°C to +8°C at health center; OPV most heat-sensitive; DPT/Hep B freeze-sensitive (use shake test) - FEFO rotation; VVM monitoring - Do not withhold vaccines for minor illness; true contraindications rare **On Disease Surveillance:** - PIDSR system; notifiable diseases (immediately vs. weekly) under the Philippine Health Code - Nurse responsibility: recognize, report, document, collect specimens, implement isolation **On TB Control:** - DOTS strategy: 5 pillars; Xpert MTB/RIF first-line diagnostic - Category I: 2HRZE/4HR (6 months); directly observed every dose - TB treatment success through adherence; contact tracing; TPT for child contacts - Rifampicin orange-red urine (normal); ethambutol color blindness risk; streptomycin ototoxicity **On Dengue Control:** - Aedes aegypti, day-biter, breeds in clean water containers; 4 serotypes - 4-S strategy: search and destroy, self-protection, seek early consultation, support fogging - Warning signs: severe abdominal pain, vomiting, bleeding, lethargy → hospital referral - Home care: hydration, acetaminophen (avoid aspirin) **On Other Endemic Diseases:** - Know endemic areas and control strategies for malaria, schistosomiasis, filariasis, leprosy, rabies - Rabies PEP is time-critical; wound care (soap and water, antiseptic) first step **NLE Exam Strategies:** 1. **Scenario-based questions:** Expect questions where you apply knowledge to patient/community scenarios. Example: "A mother brings her 6-week-old infant for immunization. The child has a mild cough. What should the nurse do?" (Answer: vaccinate; minor illness is not a contraindication) 2. **Prioritization questions:** Given multiple interventions or diseases, prioritize based on Maslow's hierarchy and disease burden. Example: "A health center has limited vaccines. Which disease prevention is highest priority?" (Consider which disease has highest mortality, is vaccine-preventable, and is feasible to control) 3. **Program-based questions:** Test knowledge of specific Philippine programs (EPI, NTP, PIDSR). Example: "A TB patient misses 5 consecutive doses of anti-TB medication. What is the primary nursing concern?" (Drug resistance; need for directly observed therapy and re-engagement) 4. **Standard calculation and schedule questions:** Memorize the Philippine EPI schedule and doses. Example: "A child has received BCG at birth and Pentavalent at 6, 10, and 14 weeks. At what age should the next measles vaccination be given?" (Answer: 9 months for MCV1) 5. **Prevention level classification:** Be clear on which level (primary, secondary, tertiary) each intervention addresses. Example: "Identifying TB contacts and offering TB preventive therapy is which level of prevention?" (Answer: secondary—early detection and prevention of disease progression) **Conclusion: The Community Nurse as a Change Agent in Communicable Disease Control** Communicable disease control is not a one-time intervention but a sustained, integrated approach that requires the community nurse to be a **health educator, program implementer, advocate, and community mobilizer**. The eradication of smallpox globally and the near-eradication of polio demonstrate that communicable diseases can be controlled and eliminated when there is political commitment, adequate resources, community participation, and dedicated health workers. In the Philippines, the community nurse is often the **first point of contact** for vaccine delivery, disease detection, and health education. By mastering the concepts in this chapter—the levels of prevention, immunity concepts, the EPI and DOTS strategies, disease surveillance, and endemic disease control—the nurse is equipped to make a tangible, life-saving impact on community health. Every vaccination prevents a case of disease; every TB patient cured prevents transmission to family and community; every dengue case detected and managed early prevents severe disease and death; every community education session builds awareness and health literacy. The NLE tests not just knowledge but clinical judgment and the ability to apply evidence-based practices in real-world, resource-limited settings. As you prepare for the exam, internalize the **"why"** behind each intervention: why vaccines are cold-chained, why TB treatment adherence is critical, why dengue warning signs matter. This conceptual understanding will help you answer NLE questions with confidence and, more importantly, will prepare you to deliver evidence-based, compassionate community health nursing care that saves lives and prevents disease.